Premium
Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling
Author(s) -
Rüdebusch Julia,
Benkner Alexander,
Nath Neetika,
Fleuch Lina,
Kaderali Lars,
Grube Karina,
Klingel Karin,
Eckstein Gertrud,
Meitinger Thomas,
Fielitz Jens,
Felix Stephan B.
Publication year - 2022
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.15333
Subject(s) - riociguat , heart failure , medicine , ejection fraction , cardiology , pressure overload , ventricular remodeling , fibrosis , endocrinology , hemodynamics , chronic thromboembolic pulmonary hypertension , cardiac hypertrophy
Heart failure is associated with an impaired NO-soluble guanylyl cyclase (sGC)-cGMP pathway and its augmentation is thought to be beneficial for its therapy. We hypothesized that stimulation of sGC by the sGC stimulator riociguat prevents pathological cardiac remodelling and heart failure in response to chronic pressure overload.